News

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023.

“Hundreds of organizations have been selected to join each network. Having been asked to become a member on both networks is a rare opportunity — SRI is honored,” said Kathlynn Brown, president of SRI’s Biosciences division.

Through these memberships, SRI gains access to potential funding and flexible contracting for faster award execution compared to traditional contract processes. This means that people can benefit from advanced healthcare innovations in discovery and treatment without having to wait for years.

The Customer Experience Hub seeks to make healthcare treatments accessible to everyone, from rural areas to cities. The Investor Catalyst Hub seeks to accelerate the broad commercialization of groundbreaking biomedical solutions. The networks utilize an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and minority-serving institutions, to deliver scalable positive healthcare outcomes for all Americans.

SRI delivers bioscience, applied research, and commercial transfer expertise — moving important health technologies from the research lab into the real world.

“SRI’s mission is to make an impact so people can live healthier and safer lives,” said Brown. “We’re proud to be a part of this nationwide health initiative to advance our innovations where they can make a difference. Our work in precision medicine is essential, but without government and commercial support, people, especially in rural and underserved areas, cannot benefit.”

SRI joins a nationwide network of organizations aligned to ARPA-H’s overarching mission of improving health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. ARPANET-H hubs and spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

“The ARPA-H model is advantageous because the trusted members can move quickly, so the proper healthcare can be delivered faster and safer,” Brown said.

 

Learn more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin